RecruitingNCT06174116
Lumateperone or placebo added to clozapine: metabolic effects
About this title
Read the official source — NCT06174116Medication studyAges 18–65United StatesSchizophrenia
Understand this study
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- WorcesterSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 2, 2024
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 50
- Sponsor
- University of Massachusetts, Worcester
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06174116
- Official title
Show the full official title
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Worcester
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Massachusetts, Worcester, a university.
Does this study involve medication?
Yes. The study involves medication, including Lumateperone and Placebo.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
